Ready-to-graft microtissue formats

To unleash the therapeutic potential of stem cell-derived cell therapies


Our goal is to bring the benefits of C-Stem™ as fast as possible to patients. To do so, we advance proprietary cell therapy programs and partner with leading initiatives from the industry and the academia.

Lead programme

Microtissues of mature dopaminergic neurons to cure Parkinson's disease

In contrast with cell therapy approaches based on progenitors, the C-Stem™ technology generates 3D neurospheres of mature dopaminergic neurons. Preclinical studies demonstrated best-in-class results. TreeFrog is  now preparing a first-in-human trial in 2024.
Neural microtissue composed of mature dopaminerguic neurons differentiated from human induced pluripotent stem cells cultured in 3D using C-Stem™ technology
0 x
more engrafted dopaminergic neurons
2 x
faster motor function recovery
Co-development & Licensing opportunities

Contact our team

Pascale Berthet TreeFrog

Pascale Berthet, MSc

CHief Business development officer

Cell Therapy Pipeline I iPS-derived cell therapies I Allogeneic Stem Cell Therapies

TreeFrog Therapeutics is advancing a pipeline of hiPSC-derived cell therapies based on the C-Stem technology. Our lead programme is an iPS-based cell therapy for Parkinson’s disease, which will reach IND and Phase I in 2024. We are also developing allogeneic therapies for heart failure with hiPSC-derived cardiac cells, iPS-derived HSC transplants with the EFS, iPS-derived CAR & NK cell therapies for oncology, iPS-derived cell therapies for AMD, as well as exploratory cell therapies for hepatic and pancreatic diseases (acute liver failure and Diabetes Type I)